Participated · Series C · Jan 2026

Quadric develops the Chimera GPNPU, a fully programmable general-purpose AI inference processor architecture optimized for on-device AI/ML inference and classic DSP and control algorithms. The Chimera processors scale from 1 to over 3,200 TOPS in multi-chiplet configurations and support both convolutional and transformer-based models, including on-device LLM inference and emerging VLA world models. Quadric's software toolchain converts AI models into C++ and enables SoC teams to program in Python or C++, allowing models to be updated on shipped silicon. The company offers automotive-grade safety-enhanced versions of its architecture and emphasizes a software-updatable approach so the same silicon can run models published after the chip was designed. Quadric reported that product revenues more than tripled in the prior year and that it reached profitability. The company is headquartered in Burlingame, California.

Participated · Series B · Dec 2020

ConsejoSano’s core product is the Cultural Determinants of Health Engine, a two-way communications platform that uses cultural insights to build patient trust and engages people in more than 25 languages via texting, email, phone, and mail. The platform is used by four of the top five managed care plans and currently engages 1.5 million patients across 12 states while collecting over 2 million cultural data points. ConsejoSano says its technology has enabled more than 50,000 telemedicine appointments for lower-income Medicaid and Medicare patients and supported a roughly 340% increase in two-way interactions. The company reported nearly 400% growth in annually recurring revenue from 2019 to 2020. ConsejoSano is applying its platform to COVID-19 education and outreach for underserved populations to improve preventative care, chronic disease management, and overall health equity. The company’s stated mission is to close gaps in multicultural patient care by delivering culturally- and linguistically-familiar communications to diverse populations. ConsejoSano is a San Francisco-based digital health platform that helps Spanish speakers navigate America’s healthcare system. Led by founder and CEO Abner Mason, it offers an integrated service including HIPPA compliant multi-channel messaging, care navigation, data analytics and 24/7 access to native-Spanish-speaking medical navigators. The majority of its clients are health plans, employers and at-risk providers seeking to increase engagement from Spanish-speaking customers, employees and patients. In February 2017 the company raised $4.9m in a Series A round, bringing total funding to $7.2m. The Series A was led by 7wire Ventures with participation from Tufts Health Ventures, TOTAL Impact Capital, Wanxiang Healthcare Investments, Acumen, Oxeon Partners and Impact Engine. ConsejoSano will use the funds to develop its capability to collect data analytics to improve preventive care for Spanish speakers.

Participated · Series C · Apr 2016

Livongo Health is a Mountain View, California-based consumer digital health company that offers Livongo for Diabetes and Livongo for Hypertension. Led by CEO Glen Tullman, the company combines consumer health technology, personalized recommendations, and real-time support to drive behavior change at the point of impact. Powered by advanced data science, Livongo creates personalized experiences so members receive the right information, tools, and support at the right time. The company announced a $105M funding round and will use the proceeds to accelerate growth, continue investing in data science, deepen integration with clients and partners, and develop its comprehensive consumer platform. Livongo also announced a strategic partnership with Cambia Health Solutions to improve member health beginning with diabetes, and to co-develop and market new offerings. In conjunction with the financing, Kinnevik’s Senior Investment Director Chris Bischoff is joining Livongo’s board of directors. Livongo Health offers a cellular-connected blood glucose monitor coupled with monitoring and coaching services that intervene when readings fall outside normal bounds. Readings are sent to Livongo’s monitoring service, which issues recommendations or connects users to a specialist for high or low values. The company emphasizes rapid human response—aiming to reach users within 90 seconds—and lowers usage barriers by providing free test strips and persistent data storage. Livongo works with self-insured employers and pharmacy benefit providers to distribute its product to patients. Management says the company, a little more than three years old, has demonstrated potential payer savings of up to $100 per member per month. Future plans include international expansion and broadening the platform to manage other chronic conditions such as hypertension and depression. Operational metrics cited include a coach-to-member ratio of roughly one coach per 2,500 members and the need to scale educator staffing as membership grows. Livongo Health offers a diabetes management platform that combines a cellular two-way interactive glucose meter, a smart cloud for personalized analytics, and certified diabetes educators to provide real-time, contextual support. The company pairs technology, data science, and coaching to drive clinical improvement, member satisfaction, and cost savings for payers and employers. Livongo reports rapid adoption among self-insured employers, payers, and healthcare providers and is expanding nationally with existing clients such as Lowe’s. The platform is consumer-directed and designed to integrate patients’ care teams including family and medical professionals. The company intends to use new capital to support growth, accelerate the launch of new products and services, and expand into new market segments. Founded in September 2014 by CEO Glen Tullman, Livongo Health offers a digital chronic disease management platform that began with a diabetes program called Livongo for Diabetes. The company supplies users with a blood glucose smartmeter that uploads biometric data to a cloud-based inference engine using historical data, clinical rules and predictive modeling to generate actionable information. Livongo’s product lets members inform family and care teams in real time and is targeted at people with Type 1 and Type 2 diabetes. The company has signed agreements to provide its program to employees of self-insured employers including Office Depot, Iron Mountain and multiple Fortune 100 companies. Livongo plans to further develop its chronic disease management ecosystem and accelerate adoption of its diabetes program among self-insured employers, healthcare providers and payers. The article notes a $20M Series B financing to support these efforts. Livongo Health builds digital health tools and services to help people with chronic conditions access technology, real-time personalized information, and support from a chosen care team. The company is initially focusing on diabetes and offers an FDA-cleared two-way interactive glucometer, unlimited monitoring supplies, cloud-based analytics, and real-time monitoring and support. Led by Glen Tullman, Livongo has partnerships with HealthCare Partners and self-funded employers including Office Depot. The company is based in Palo Alto and also has operations in Chicago. Livongo expects a number of additional strategic partnerships to be announced in the coming months. Financially, the company recently closed a named financing round (see deal details).